Hanmi Pharm. Co., Ltd. (KRX:128940)
South Korea · Delayed Price · Currency is KRW 400,000
-28,500 (-6.65%)
Last updated: Jun 10, 2026, 2:01 PM KST
Hanmi Pharm. Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,549,509 | 1,547,531 | 1,495,502 | 1,490,887 | 1,331,547 | 1,203,186 |
Other Revenue | 0 | -0 | - | - | -0 | - |
| 1,549,509 | 1,547,531 | 1,495,502 | 1,490,887 | 1,331,547 | 1,203,186 | |
Revenue Growth (YoY) | 4.50% | 3.48% | 0.31% | 11.97% | 10.67% | 11.83% |
Cost of Revenue | 661,405 | 663,124 | 678,465 | 661,638 | 612,994 | 570,433 |
Gross Profit | 888,104 | 884,407 | 817,037 | 829,249 | 718,553 | 632,752 |
Selling, General & Admin | 428,195 | 430,773 | 421,960 | 426,789 | 406,146 | 361,309 |
Research & Development | 207,481 | 195,834 | 178,891 | 181,769 | 154,317 | 146,027 |
Operating Expenses | 677,515 | 660,536 | 604,526 | 604,364 | 564,657 | 507,336 |
Operating Income | 210,588 | 223,870 | 212,511 | 224,885 | 153,896 | 125,416 |
Interest Expense | -15,292 | -16,986 | -24,374 | -28,508 | -22,647 | -16,577 |
Interest & Investment Income | 8,279 | 7,266 | 5,666 | 4,618 | 7,856 | 5,722 |
Earnings From Equity Investments | -18.91 | -7.45 | -9.2 | 1,258 | -8,537 | -4.02 |
Currency Exchange Gain (Loss) | 9,917 | 1,434 | 9,318 | 1,039 | -2,641 | 13.07 |
Other Non Operating Income (Expenses) | 951.15 | -3,949 | -29,309 | -4,571 | -3,620 | -9,277 |
EBT Excluding Unusual Items | 214,424 | 211,628 | 173,802 | 198,721 | 124,308 | 105,293 |
Gain (Loss) on Sale of Investments | 4,329 | 4,762 | -87.92 | 2,630 | 47.09 | - |
Gain (Loss) on Sale of Assets | 16.26 | 101.2 | 27.74 | 1,769 | 451.65 | -1,062 |
Asset Writedown | -3,088 | -3,013 | -2,488 | -9,153 | -3,794 | -535.2 |
Pretax Income | 215,681 | 213,478 | 171,254 | 193,967 | 121,013 | 103,697 |
Income Tax Expense | 22,116 | 26,342 | 30,823 | 28,601 | 19,454 | 22,218 |
Earnings From Continuing Operations | 193,565 | 187,136 | 140,431 | 165,366 | 101,558 | 81,478 |
Minority Interest in Earnings | -21,126 | -17,581 | -19,116 | -19,135 | -18,766 | -14,453 |
Net Income | 172,439 | 169,554 | 121,315 | 146,231 | 82,792 | 67,025 |
Net Income to Common | 172,439 | 169,554 | 121,315 | 146,231 | 82,792 | 67,025 |
Net Income Growth | 58.32% | 39.76% | -17.04% | 76.63% | 23.52% | 460.45% |
Shares Outstanding (Basic) | 13 | 13 | 13 | 13 | 13 | 13 |
Shares Outstanding (Diluted) | 13 | 13 | 13 | 13 | 13 | 13 |
Shares Change (YoY) | 0.08% | 0.07% | -0.08% | -0.09% | -0.12% | -0.11% |
EPS (Basic) | 13597.64 | 13371.57 | 9566.83 | 11522.12 | 6517.33 | 5269.87 |
EPS (Diluted) | 13587.92 | 13362.00 | 9566.83 | 11522.12 | 6517.33 | 5269.87 |
EPS Growth | 58.19% | 39.67% | -16.97% | 76.79% | 23.67% | 461.07% |
Free Cash Flow | 153,918 | 130,048 | 154,226 | 189,186 | 131,890 | 181,974 |
Free Cash Flow Per Share | 12128.64 | 10248.77 | 12162.13 | 14906.67 | 10382.37 | 14307.73 |
Gross Margin | 57.32% | 57.15% | 54.63% | 55.62% | 53.96% | 52.59% |
Operating Margin | 13.59% | 14.47% | 14.21% | 15.08% | 11.56% | 10.42% |
Profit Margin | 11.13% | 10.96% | 8.11% | 9.81% | 6.22% | 5.57% |
Free Cash Flow Margin | 9.93% | 8.40% | 10.31% | 12.69% | 9.90% | 15.12% |
EBITDA | 309,618 | 322,679 | 309,842 | 323,339 | 250,738 | 214,502 |
EBITDA Margin | 19.98% | 20.85% | 20.72% | 21.69% | 18.83% | 17.83% |
D&A For EBITDA | 99,029 | 98,809 | 97,331 | 98,454 | 96,842 | 89,086 |
EBIT | 210,588 | 223,870 | 212,511 | 224,885 | 153,896 | 125,416 |
EBIT Margin | 13.59% | 14.47% | 14.21% | 15.08% | 11.56% | 10.42% |
Effective Tax Rate | 10.25% | 12.34% | 18.00% | 14.74% | 16.08% | 21.43% |
Advertising Expenses | - | 73,817 | 78,789 | 76,034 | 72,627 | 62,201 |